|
Genes differentially expressed in human CD4+CD25+ regulatory vs CD4+CD25- naive T cells |
||
| Gene symbol |
Gene name |
Autoimmunity |
|
|
||
| NINJ2 |
Ninjurin 2 |
|
| ACTN1 |
Actinin, alpha 1 |
SLE, CHA |
| NELL2 |
NEL-like 2 |
|
| ITGB2 |
Integrin, β2 |
UC, MC, COPD, T2D, AS, LAD-1, RA, ALPS, SLE |
| TIAF1 |
TGFB1-induced antiapoptotic factor 1 |
|
| TP53INP1 |
Tumor protein p53 inducible nuclear protein 1 |
|
| TRAF1a |
TNF receptor-associated factor 1 |
|
| LGALS1 |
Galectin 1 |
JIA, RA, IBD |
| LGALS3a |
Galectin 3 |
RA, JIA |
| GZMA |
Granzyme A |
T1D, RA, SLE, IBD |
| GZMK |
Granzyme K |
|
| PTTG1 |
Pituitary tumor-transforming 1 |
Diabetes |
| TRIB1 |
Tribbles homolog 1 |
|
| S100A10 |
S100 calcium binding protein A10 |
|
| CEB1 |
Hect domain and RLD 5 |
|
| SLAMF1 |
Signaling lymphocytic activation molecule family member 1 |
SLE, X-linked XLP, RA, MS |
| S100A4 |
S100 calcium binding protein A4 |
RA |
| PIM1 |
Pim-1 oncogene |
|
| ID2 |
Inhibitor of DNA binding 2 |
Diabetes |
| FHIT |
Fragile hisT1Dine triad gene |
|
| RBMS1 |
RNA binding motif, single stranded interacting protein 1 |
|
| IFITM1 |
Interferon induced transmembrane protein 1 |
|
| IL2RAa |
Interleukin 2 receptor, alpha |
T1D, profound cellular immunodefiency |
| TNFRSF1Ba |
Tumor necrosis factor receptor superfamily, member 1B |
MC, UC, MS, SLE |
| CCR5 |
Chemokine (C-C motif) receptor 5 |
MS, Grave's disease, RA |
| GPR2 |
Chemokine (C-C motif) receptor 10 |
Autoimmune skin diseases |
| IL2RB |
Interleukin 2 receptor, beta |
ITP, RA, osteoarthritis, hemolytic anemia |
| G1P2 |
Interferon, alpha-inducible protein |
|
| IL1RL2 |
Interleukin 1 receptor-like 2 |
|
| IL7R |
Interleukin 7 receptor |
SCID, RA, SLE |
| CCR7a |
Chemokine (C-C motif) receptor 7 |
Diabetes, SLE, MS, RA, JIA |
| TNFSF5 |
CD40 ligand (TNF superfamily, member 5, hyper-IgM syndrome) |
HIGM1, Alzheimer disease, T1D, SLE, MS, AS, ITP |
| CCL5 |
Chemokine (C-C motif) ligand 5 |
EAT, MS, diabetes, SLE, RA |
| TNFRSF10B |
Tumor necrosis factor receptor superfamily, member 10b |
MS, RA |
| SDC4 |
Syndecan 4 |
|
| CTLA4a |
Cytotoxic T-lymphocyte-associated protein 4 |
T1D, Grave's disease, SLE |
| TFRC |
Transferrin receptor |
|
| AKAP2 |
A kinase (PRKA) anchor protein 2 |
|
| DGKA |
Diacylglycerol kinase, alpha |
|
| PITPNC1 |
PhosphaT1Dylinositol transfer protein, cytoplasmic 1 |
|
| TRGV9 |
T cell receptor gamma variable 9 |
|
| CD81 |
CD81 antigen |
|
| PECAM1 |
Platelet/endothelial cell adhesion molecule |
ITP, diabetes, AS, RA, CIA, MS |
| FOXP3 |
Forkhead box P3 |
IPEX, T1D |
| GATA3 |
GATA binding protein 3 |
RA, HDR syndrome |
| BHLHB2 |
Basic helix-loop-helix domain containing, class B, 2 |
SLE |
| SATB1 |
Special AT-rich sequence binding protein 1 |
|
| STAT4 |
Signal transducer and activator of transcription 4 |
MC, EAE, UC, diabetes, COPD, SLE, arthritis |
| STAT6 |
Signal transducer and activator of transcription 6 |
EAE, RA, autoimmune uveitis, diabetes |
| MYC |
v-myc Myelocytomatosis viral oncogene homolog |
Diabetes, RA, SLE |
| TCF7 |
Transcription factor 7 (T-cell specific, HMG-box) |
T1D |
| XBP1 |
X-box binding protein 1 |
T2D, RA |
| CNOT2 |
CCR4-NOT transcription complex, subunit 2 |
|
| HLA-DMA |
Major histocompatibility complex, class II, DM alpha |
T1D, SLE, RA |
| HLA-DRB1 |
Major histocompatibility complex, class II, DR beta 1 |
RA, MS, sarcoidosis, Sjögren's syndrome, Grave's disease, T1D |
| HLA-DRB3 |
Major histocompatibility complex, class II, DR beta 3 |
SLE, RA, MS, sarcoidosis, Sjögren's syndrome, Grave's disease |
| GBP2 |
Guanylate binding protein 2, interferon-inducible |
|
| GBP5 |
Guanylate binding protein 5 |
|
| SLC40A1 (a) |
Solute carrier family 40 (iron-regulated transporter), member 1 |
|
| SHMT2 (b) |
Serine hydroxymethyltransferase 2 (mitochondrial) |
|
| EPSTI1 |
Epithelial stromal interaction 1 |
|
| NOSIP |
Nitric oxide synthase interacting protein |
|
|
aGenes that were additionally found to be induced upon retroviral over-expression of FOXP3 in CD4+CD25- T cells. ALPS, autoimmune lymphoproliferative syndrome; AS, atherosclerosis; CHA, autoimmune chronic active hepatitis; CIA, collagen-induced arthritis; COPD, chronic obstructive pulmonary disease; EAE, experimental autoimmune encephalomyelitis; EAT, experimental autoimmune thyroiditis; HIGM1, hyper-IgM immunodefiency syndrome type I; IPEX, immunodysregulation, polyendocrinopathy, and entheropathy, X-linked; JIA, juvenile idiopathic arthritis; IBD, inflammatory bowel disease; ITP, idiopathic thrombocytopenic purpura; LAD-1, leukocyte adhesion deficiency-1; MC, Morbus Crohn; MS, multiple sclerosis; RA, rheumatoid arthritis; SCID, severe combined immunodefiency; SLE, systemic lupus erythematosus; T1D, type I diabetes; T2D, type II diabetes; UC, ulcerative colitis; XLP, X-linked lymphoproliferative syndrome. | ||
Pfoertner et al. Genome Biology 2006 7:R54 doi:10.1186/gb-2006-7-7-r54 |
||